Aclaris Therapeutics (ACRS) Operating Income (2017 - 2025)
Historic Operating Income for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$17.1 million.
- Aclaris Therapeutics' Operating Income fell 6377.61% to -$17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.3 million, marking a year-over-year decrease of 23111.46%. This contributed to the annual value of -$141.9 million for FY2024, which is 4578.51% down from last year.
- Aclaris Therapeutics' Operating Income amounted to -$17.1 million in Q3 2025, which was down 6377.61% from -$18.4 million recorded in Q2 2025.
- Aclaris Therapeutics' Operating Income's 5-year high stood at -$4.0 million during Q4 2023, with a 5-year trough of -$99.7 million in Q4 2024.
- For the 5-year period, Aclaris Therapeutics' Operating Income averaged around -$24.9 million, with its median value being -$20.3 million (2021).
- In the last 5 years, Aclaris Therapeutics' Operating Income surged by 8608.27% in 2023 and then tumbled by 236293.55% in 2024.
- Quarter analysis of 5 years shows Aclaris Therapeutics' Operating Income stood at -$22.9 million in 2021, then fell by 27.02% to -$29.1 million in 2022, then soared by 86.08% to -$4.0 million in 2023, then plummeted by 2362.94% to -$99.7 million in 2024, then skyrocketed by 82.8% to -$17.1 million in 2025.
- Its Operating Income was -$17.1 million in Q3 2025, compared to -$18.4 million in Q2 2025 and -$18.1 million in Q1 2025.